"Alendronate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
Descriptor ID |
D019386
|
MeSH Number(s) |
D02.705.429.500.100
|
Concept/Terms |
Alendronate- Alendronate
- Aminohydroxybutane Bisphosphonate
- Bisphosphonate, Aminohydroxybutane
- 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
- 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate
Alendronate Sodium- Alendronate Sodium
- Sodium, Alendronate
- Alendronate Monosodium Salt, Trihydrate
|
Below are MeSH descriptors whose meaning is more general than "Alendronate".
Below are MeSH descriptors whose meaning is more specific than "Alendronate".
This graph shows the total number of publications written about "Alendronate" by people in this website by year, and whether "Alendronate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 2 | 0 | 2 |
1997 | 1 | 0 | 1 |
1999 | 1 | 0 | 1 |
2000 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2007 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2019 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alendronate" by people in Profiles.
-
Alendronate conjugate for targeted delivery to bone-forming prostate cancer. Talanta. 2023 May 01; 256:124308.
-
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. Endocr Pract. 2022 Oct; 28(10):1078-1085.
-
ATRAID regulates the action of nitrogen-containing bisphosphonates on bone. Sci Transl Med. 2020 05 20; 12(544).
-
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. J Bone Miner Res. 2020 01; 35(1):36-52.
-
Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol. 2013 Oct; 108(10):1576-83.
-
Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. Value Health. 2011 Dec; 14(8):1109-16.
-
Corticosteroid-induced osteoporosis in children: outcome after two-year follow-up, risk factors, densitometric predictive cut-off values for vertebral fractures. Clin Exp Rheumatol. 2007 Mar-Apr; 25(2):329-35.
-
The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006 Jun 12; 166(11):1209-17.
-
A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother. 2005 Sep; 3(3):127-36.
-
14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol. 2002 Sep; 29(9):1965-74.